Braveheart Bio, Inc.
Braveheart Bio, Inc.
Your view on BRVE
Overview
What the company does, where it operates, and who runs it.
About Braveheart Bio, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Travis Murdoch
- Headquarters
- One Letterman Drive, Building A, Suite A4-300, San Francisco, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Travis Murdoch
- Headquarters
- One Letterman Drive, Building A, Suite A4-300, San Francisco, CA, US
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Braveheart Bio, Inc. from FRC's valuation model, read against the market price. BRVE last traded at $20.90; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Braveheart Bio, Inc.. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Braveheart Bio, Inc.. Braveheart Bio, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Braveheart Bio, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$40.00
Median
$46.50
High
$48.00
Average target · 4 new targets in the last 3 months, average $45.25
Analyst Ratings
- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Braveheart Bio, Inc.. Braveheart Bio, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Braveheart Bio, Inc. valued side by side against its closest peers. Braveheart Bio, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Braveheart Bio, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Braveheart Bio, Inc.. Coverage tracks Braveheart Bio, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Braveheart Bio, Inc.